[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,389,940
  • Shares Outstanding, K 64,311
  • Annual Sales, $ 46,020 K
  • Annual Income, $ -130,150 K
  • EBIT $ -158 M
  • EBITDA $ -162 M
  • 60-Month Beta 1.89
  • Price/Sales 138.15
  • Price/Cash Flow N/A
  • Price/Book 9.70

Options Overview Details

View History
  • Implied Volatility 45.12% (+2.27%)
  • Historical Volatility 43.41%
  • IV Percentile 25%
  • IV Rank 36.27%
  • IV High 61.81% on 10/07/25
  • IV Low 35.62% on 11/17/25
  • Expected Move (DTE 4) 0.00 (0.00%)
  • Put/Call Vol Ratio 26.73
  • Today's Volume 416
  • Volume Avg (30-Day) 164
  • Put/Call OI Ratio 1.48
  • Today's Open Interest 4,935
  • Open Int (30-Day) 4,916
  • Expected Range 103.50 to 103.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.23
  • Number of Estimates 5
  • High Estimate $5.44
  • Low Estimate $-0.30
  • Prior Year $-0.55
  • Growth Rate Est. (year over year) +505.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
95.40 +8.49%
on 04/13/26
107.00 -3.27%
on 04/22/26
+4.68 (+4.74%)
since 04/10/26
3-Month
77.00 +34.42%
on 02/23/26
107.84 -4.02%
on 04/01/26
+20.01 (+23.97%)
since 02/11/26
52-Week
43.20 +139.58%
on 05/14/25
107.84 -4.02%
on 04/01/26
+60.53 (+140.87%)
since 05/09/25

Most Recent Stories

More News
Protagonist Therapeutics: Q1 Earnings Snapshot

Protagonist Therapeutics: Q1 Earnings Snapshot

PTGX : 103.50 (+4.17%)
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

ICOTYDEâ„¢ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible...

PTGX : 103.50 (+4.17%)
PTGX: The Partnership Everyone's Celebrating Might Be the Problem

Barchart Research What to Expect from PTGX Earnings PTGX Generated May 4, 2026 Current Price $99.52 EPS Estimate $$-0.65 Consensus Rating Strong Buy Average Move 3.25% PTGX: The Partnership Everyone's...

PTGX : 103.50 (+4.17%)
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera

PTGX : 103.50 (+4.17%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accordance...

PTGX : 103.50 (+4.17%)
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis

PTGX : 103.50 (+4.17%)
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill

PTGX : 103.50 (+4.17%)
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study ...

PTGX : 103.50 (+4.17%)
TAK : 16.36 (-0.61%)
Protagonist Therapeutics: Q4 Earnings Snapshot

Protagonist Therapeutics: Q4 Earnings Snapshot

PTGX : 103.50 (+4.17%)
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.)

PTGX : 103.50 (+4.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 111.29
2nd Resistance Point 108.31
1st Resistance Point 105.90
Last Price 103.50
1st Support Level 100.52
2nd Support Level 97.54
3rd Support Level 95.13

See More

52-Week High 107.84
Last Price 103.50
Fibonacci 61.8% 83.15
Fibonacci 50% 75.52
Fibonacci 38.2% 67.89
52-Week Low 43.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.